Treace Medical Concepts, Inc. (TMCI)Healthcare | Medical Devices | Ponte Vedra, United States | NasdaqGS
1.94 USD
+0.07
(3.743%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.99 +0.05 (2.464%) ⇧ (April 17, 2026, 7:27 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:55 a.m. EDT
Despite the $175M loan providing short-term liquidity and a massive 122% analyst price target upside to $4.25, TMCI is a fundamental value trap resulting from core revenue collapse (-9% growth) and negative operating cash flow (-$15.9M). The recent ~14% price gain is a dead cat bounce against heavy short cover, not a reversal of the structural deterioration. With no dividends and a net-burn balance sheet, the stock offers no safety margin; the 'buy' recommendations rely on valuation multiples that are not supported by earnings, making long-term participation hazardous at current levels. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.146050 |
| AutoTheta | 0.221220 |
| MSTL | 0.415970 |
| AutoETS | 0.416145 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 15% |
| H-stat | 40.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 82.286 |
| Revenue per Share | 3.362 |
| Market Cap | 125,681,808 |
| Forward P/E | -2.16 |
| Beta | 0.88 |
| Profit Margins | -27.74% |
| Website | https://www.treace.com |
As of April 19, 2026, 12:55 a.m. EDT: Options data shows a distinct skew towards long-aged ATM calls (9-month $2.5 strike with 1k volume) versus negligible short-dated call liquidity, indicating speculative positioning for a medium-term rebound rather than immediate volatility. The implied volatility for near-term (April) and medium-term calls is non-existent or near zero, while a tiny amount of put flow exists in the $5.00 strikes for June and September, suggesting minimal hedging desire at current price levels. The lack of short-term call volume implies speculators do not believe the stock will surge immediately but anticipate a future move if it holds above current support.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.69875777 |
| Address1 | 100 Palmetto Park Place |
| All Time High | 37.17 |
| All Time Low | 1.17 |
| Ask | 1.99 |
| Ask Size | 3 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 1,639,970 |
| Average Daily Volume3 Month | 884,395 |
| Average Volume | 884,395 |
| Average Volume10Days | 1,639,970 |
| Beta | 0.878 |
| Bid | 1.89 |
| Bid Size | 3 |
| Board Risk | 7 |
| Book Value | 1.367 |
| City | Ponte Vedra |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.94 |
| Current Ratio | 4.311 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.98 |
| Day Low | 1.86 |
| Debt To Equity | 82.286 |
| Display Name | Treace Medical Concepts |
| Earnings Call Timestamp End | 1,772,197,200 |
| Earnings Call Timestamp Start | 1,772,197,200 |
| Earnings Timestamp | 1,772,199,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -44,531,000 |
| Ebitda Margins | -0.20937 |
| Enterprise To Ebitda | -3.334 |
| Enterprise To Revenue | 0.698 |
| Enterprise Value | 148,479,488 |
| Eps Current Year | -0.91 |
| Eps Forward | -0.9 |
| Eps Trailing Twelve Months | -0.93 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.657 |
| Fifty Day Average Change | 0.2830001 |
| Fifty Day Average Change Percent | 0.17079066 |
| Fifty Two Week Change Percent | -69.87578 |
| Fifty Two Week High | 7.78 |
| Fifty Two Week High Change | -5.84 |
| Fifty Two Week High Change Percent | -0.75064266 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 0.7700001 |
| Fifty Two Week Low Change Percent | 0.65811974 |
| Fifty Two Week Range | 1.17 - 7.78 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,184,600,000 |
| Float Shares | 47,945,078 |
| Forward Eps | -0.9 |
| Forward P E | -2.1555557 |
| Free Cashflow | -10,086,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 450 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.79811996 |
| Gross Profits | 169,752,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24789 |
| Held Percent Institutions | 0.55507 |
| Implied Shares Outstanding | 64,784,436 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-04-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. |
| Long Name | Treace Medical Concepts, Inc. |
| Market | us_market |
| Market Cap | 125,681,808 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_282593338 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -59,002,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 125,033,961 |
| Number Of Analyst Opinions | 4 |
| Open | 1.89 |
| Operating Cashflow | -15,970,000 |
| Operating Margins | -0.09472 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 904 373 5940 |
| Post Market Change | 0.047799945 |
| Post Market Change Percent | 2.4639146 |
| Post Market Price | 1.9878 |
| Post Market Time | 1,776,468,434 |
| Previous Close | 1.87 |
| Price Eps Current Year | -2.1318681 |
| Price Hint | 4 |
| Price To Book | 1.4191661 |
| Price To Sales Trailing12 Months | 0.59091544 |
| Profit Margins | -0.27741 |
| Quick Ratio | 2.965 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.8 |
| Region | US |
| Regular Market Change | 0.0700001 |
| Regular Market Change Percent | 3.74332 |
| Regular Market Day High | 1.98 |
| Regular Market Day Low | 1.86 |
| Regular Market Day Range | 1.86 - 1.98 |
| Regular Market Open | 1.89 |
| Regular Market Previous Close | 1.87 |
| Regular Market Price | 1.94 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 552,196 |
| Return On Assets | -0.16605 |
| Return On Equity | -0.58936 |
| Revenue Growth | -0.09 |
| Revenue Per Share | 3.362 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,784,436 |
| Shares Percent Shares Out | 0.0681 |
| Shares Short | 4,410,141 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,670,107 |
| Short Name | Treace Medical Concepts, Inc. |
| Short Percent Of Float | 0.0855 |
| Short Ratio | 5.11 |
| Source Interval | 15 |
| State | FL |
| Symbol | TMCI |
| Target High Price | 7.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 4.25 |
| Target Median Price | 4.0 |
| Total Cash | 48,367,000 |
| Total Cash Per Share | 0.751 |
| Total Debt | 71,862,000 |
| Total Revenue | 212,690,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.15955 |
| Two Hundred Day Average Change | -2.2195501 |
| Two Hundred Day Average Change Percent | -0.5336034 |
| Type Disp | Equity |
| Volume | 552,196 |
| Website | https://www.treace.com |
| Zip | 32,081 |